Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 1,779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophagus Disorder Clear all
Completed Early Phase 1 Interventional

Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

NCT03682094
View directory record Official record
Conditions
Dysphagia
Interventions
VSL#3
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Silk Protein Microparticle-based Filler for Injection Augmentation

NCT03790956
View directory record Official record
Conditions
Vocal Cord Paralysis Unilateral, Dysphonia, Dysphagia, Oropharyngeal
Interventions
Silk Microparticle Filler Injection
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

NCT06106022
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Nov 1, 2026, 1:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy, Radiation
Procedure · Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Nov 1, 2026, 1:19 AM EDT
Terminated Not applicable Interventional

Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique

NCT03621319
View directory record Official record
Conditions
Barrett's Esophagus, High-grade Dysplasia in Barrett Esophagus, Low Grade Dysplasia in Barrett Esophagus
Interventions
Hybrid argon plasma ablation (HAPC), Radiofrequency ablation (RFA)
Device
Lead sponsor
Erbe Elektromedizin GmbH
Industry
Eligibility
18 Years to 86 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Scottsdale, Arizona • Irvine, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Nov 1, 2026, 1:19 AM EDT
Active, not recruiting Phase 2 Interventional

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

NCT03403465
View directory record Official record
Conditions
Cancer of the Cervix, Vulvar Cancer, Esophageal Cancer, Anal Canal Cancer
Interventions
FDG PET scan
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 1, 2026, 1:19 AM EDT
Terminated Phase 2 Interventional

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

NCT00256269
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Cancer
Interventions
Oxaliplatin, Irinotecan
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Nov 1, 2026, 1:19 AM EDT
Terminated Phase 2 Interventional Results available

CHFR Methylation Status Esophageal Cancer Study

NCT01372202
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Paclitaxel, Cisplatin, Oxaliplatin, 5-Fluorouracil, Radiotherapy, Esophagectomy
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Nov 1, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers

NCT02066701
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Nov 1, 2026, 1:19 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients

NCT02296528
View directory record Official record
Conditions
Oropharyngeal Dysphagia (OPD), Dysphagia
Interventions
Swallowing Expansion Device
Device
Lead sponsor
Peter Belafsky, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 1, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 2Phase 3 Interventional

Biomarkers in Phototherapy of Barrett's Esophagus

NCT00587600
View directory record Official record
Conditions
Barrett's Esophagus, High Grade Dysplasia
Interventions
Photodynamic therapy, radiofrequency ablation of barrett's esophagus
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Nov 1, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional

LITT and Pembrolizumab in Recurrent Brain Metastasis

NCT04187872
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions
LITT + Pembrolizumab
Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

NCT01913639
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Nov 1, 2026, 1:19 AM EDT
Completed No phase listed Observational

Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough

NCT02797756
View directory record Official record
Conditions
Chronic Cough (CC), Gastroesophageal Reflux (GER)
Interventions
Esophago-gastro-duodenoscopy (EGD) with biopsy, Esophageal Impedance Monitoring (EIM)
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 24 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population

NCT05778851
View directory record Official record
Conditions
Barrett Esophagus
Interventions
EsoGuard result
Device
Lead sponsor
Lucid Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Nivolumab, Docetaxel/Paclitaxel
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00183872
View directory record Official record
Conditions
Gastric Cancer, Esophageal Neoplasms
Interventions
irinotecan, docetaxel
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 1, 2026, 1:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GI Neuromuscular Pathology Prospective Registry

NCT02165059
View directory record Official record
Conditions
Gastroparesis
Interventions
Surgical Full Thickness Biopsy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux

NCT00519441
View directory record Official record
Conditions
Reflux
Interventions
pH study
Other
Lead sponsor
Kenneth Luberice
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Nov 1, 2026, 1:19 AM EDT
Completed No phase listed Observational

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

NCT03115541
View directory record Official record
Conditions
Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Nov 1, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

NCT03993353
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
Interventions
Pembrolizumab, Tadalafil
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 1, 2026, 1:19 AM EDT